Comparative Pharmacology
Head-to-head clinical analysis: MICROZIDE versus TRICHLORMAS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICROZIDE versus TRICHLORMAS.
MICROZIDE vs TRICHLORMAS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride, leading to increased excretion of water and electrolytes, and a decrease in blood volume and peripheral vascular resistance.
TRICHLORMAS is a sedative-hypnotic agent. Its mechanism of action is not fully understood but is believed to involve potentiation of GABAergic inhibition in the central nervous system, similar to other chloral derivatives. It is metabolized to trichloroethanol, which is the active hypnotic compound.
12.5-25 mg orally once daily for hypertension; 25-100 mg orally once daily for edema.
500 mg orally once daily at bedtime, increased as needed to a maximum of 1 g per day in divided doses; for insomnia, 1-2 g orally at bedtime.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours (prolonged in renal impairment; up to 30 hours in severe insufficiency).
Terminal elimination half-life is approximately 8-11 hours for the parent drug in adults with normal renal function. In patients with hepatic impairment, half-life may be prolonged up to 30 hours; in severe renal impairment, half-life of metabolites may increase significantly.
Primarily renal (approximately 70% unchanged drug; remainder as metabolites and conjugates); minimal biliary/fecal (<10%).
Primarily renal via glomerular filtration and tubular secretion; about 70-80% of the dose excreted unchanged in urine within 24 hours. The remainder is metabolized to trichloroethanol (active) and trichloroacetic acid; these metabolites are also eliminated renally.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic